🇺🇸 FDA
Pipeline program

IXIARO

IC51-325

Phase 3 mab completed

Quick answer

IXIARO for Japanese Encephalitis is a Phase 3 program (mab) at Valneva Austria GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Valneva Austria GmbH
Indication
Japanese Encephalitis
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials